Preimplantation genetic diagnosis (PGD) is an in-vitro fertilization procedure in which one or few cells are biopsied from an embryo before implantation and tested for genetic defects. PGD helps to identify genetic defects in embryos developed through IVF and assists in selective implantation of healthy embryos. It aids in preventing the transmission of hereditary disorders to offspring and allows couples to choose only embryos without genetic conditions. Factors such as rising infertility rates, increasing risk of chromosomal abnormalities with advancing maternal age, growing focus on prevention of genetic disorders, and technological advancements in PGD techniques can drive the global preimplantation genetic diagnosis market growth during the forecast period.
Market Dynamics:
Global preimplantation genetic diagnosis market growth is driven by rising infertility rates, growing focus on prevention of genetic disorders, increasing maternal age globally that leads to higher chances of chromosomal abnormalities. However, limitations of PGD, social and ethical concerns regarding PGD, and stringent regulations can hamper the market growth. Various initiatives by government and private organizations to spread awareness about PGD can offer lucrative market growth opportunities. Market players are focusing on new techniques such as next-generation sequencing to provide comprehensive chromosome screening with improved outcomes.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook